This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

This study has been completed.
Information provided by:
Hvidovre University Hospital Identifier:
First received: January 16, 2008
Last updated: February 11, 2008
Last verified: January 2008
The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We investigated whether 4 weeks of near-normalisation og blood glucose improves the potentiation of glucose-stimulated insulin secretion by GLP-1

Condition Intervention
Diabetes Mellitus Type 2 Drug: glucagon-like peptide-1 Drug: Saline

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Near Normalisation of Blood Glucose Improves the Potentiating Effect of GLP-1 on Glucose Induced Insulin Secretion in Patients With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min [ Time Frame: 180 minutes ]

Secondary Outcome Measures:
  • The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l [ Time Frame: 180 minutes ]

Enrollment: 9
Study Start Date: February 2004
Study Completion Date: December 2004
Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GLP-1
A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
Drug: glucagon-like peptide-1
continuous infusion of GLP-1 (1½ pmol/kg/min)
Experimental: Saline
A graded glucose infusion together with a continuous infusion of saline
Drug: Saline
continuous infusion of saline


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-70 years
  • Type 2 diabetes diagnosed after 30 years of age
  • BMI > 25

Exclusion Criteria:

  • Severe complications to diabetes
  • Abnormal liver og kidney function
  • Haemoglobin below the lower limit
  • Macroalbuminuria
  • Systemic disease
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00612625

Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, Denmark
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Patricia V Højberg, MD, PHD University Hospital Hvidovre
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Patricia Verdugo Højberg, MD, PHD, Patricia Verdugo Højberg Identifier: NCT00612625     History of Changes
Other Study ID Numbers: KF 01 - 198/03
KA 01 - 198/03
Study First Received: January 16, 2008
Last Updated: February 11, 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on September 21, 2017